Analyst Andrew Fein works at HC WAINWRIGHT and is covering the the Healthcare sector with 425 price targets and ratings documented since 2013 spanning on 47 stocks. Previously, Andrew Fein worked at CHARDAN CAPITAL.
Andrew Fein's average stock forecast success ratio is 33.39% with an average time for price targets to be met of 173.74 days.
Most recent stock forecast was given on ZNTL, Zentalis Pharmaceuticals Inc at 26-May-2023.
Analyst best performing recommendations are on CRBP (CORBUS PHARMACEUTICALS HOLDINGS, INC).
The best stock recommendation documented was for DNLI (DENALI THERAPEUTICS INC) at 11/6/2020. The price target of $65 was fulfilled within 5 days with a profit of $10.76 (19.84%) receiving and performance score of 39.68.
Average potential price target upside
Currently, out of the existing stock ratings of Andrew Fein - 8 which are a Buy (100%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Hold
26
$2.21 (9.29%)
32
9 days ago
4/7 (57.14%)
$6.71 (26.73%)
285
Buy
28
$4.21 (17.70%)
28
22 days ago
5/10 (50%)
$9.79 (40.33%)
175
Buy
23
$-0.79 (-3.32%)
35
22 days ago
8/14 (57.14%)
$11.27 (50.83%)
188
Buy
27
$3.21 (13.49%)
27
22 days ago
3/15 (20%)
$9.76 (40.41%)
186
Hold
20
$-3.79 (-15.93%)
20
1 months 17 days ago
7/11 (63.64%)
$3.28 (11.66%)
51
